Arsenic trioxide reduces cell growth via down-regulation of Gli2 in gastric cancer
Konferenz: BIBE 2018 - International Conference on Biological Information and Biomedical Engineering
06.06.2018 - 08.06.2018 in Shanghai, China
Tagungsband: BIBE 2018
Seiten: 4Sprache: EnglischTyp: PDF
Persönliche VDE-Mitglieder erhalten auf diesen Artikel 10% Rabatt
Autoren:
Chi, Xiaowei (Department of Clinical Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong Province, China)
Wang, Xiaoru (Department of Traditional Chinese Medicine, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong Province, China)
Liu, Jie (Department of Clinical Laboratory, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong Province, China)
Ma, Xiaoli; Jia, Yanfei (Central Laboratory, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong Province, China)
Inhalt:
The Hedgehog (Hh) pathway is activated in some human cancers, including gastric cancer(GC). The glioma associated oncogene homolog (Gli) transcription factors are critical mediators of the activated Hh pathway, and their expression may be elevated in some tumors independent of upstream Hh signaling. Thus, therapies targeting Gli transcription factors may benefit a wide spectrum of patients with mutations at different nodal points of the Hh pathway. In this study, we present evidence that arsenic trioxide (ATO) suppresses GC cell growth by inhibiting Gli2, and decreased expression of en-dogenous Gli2 target genes. Our results warrant the clinical investigation of ATO for tumors with activated Hh/Gli sig-naling, in particular patients who develop resistance to current therapies targeting the Hh pathway upstream of Gli.